Current Standard of Care in Patients with Myelodysplastic Syndromes and Future Perspectives
The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal disorders caused by somatic driver mutations affecting the hematopoietic stem and progenitor cells (HSPCs). MDS are characterized by ineffective hematopoiesis with inflammation, dysplasia, cytopenia, and a variable risk of...
Saved in:
| Main Authors: | Ioannis Chanias, Nicolas Bonadies |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2020.06.026 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Diagnostic Approach, Clinical Implications and Management of Clonal Cytopenia of Undetermined Significance
by: Ioannis Chanias, et al.
Published: (2022-12-01) -
Myelodysplastic Neoplasms: The Impact of Clonality on Inflammatory-Degenerative Diseases of the Elderly
by: Nicolas Bonadies
Published: (2024-03-01) -
Myelodysplastic syndromes: A primary care perspective
by: Keshena Naidoo, et al.
Published: (2025-07-01) -
Hematopoietic Stem Cell Transplantation in the Management of Myelodysplastic Syndrome: A Retrospective, Current, and Future Perspective
by: Qimudesiren, et al.
Published: (2024-10-01) -
Study of myelodysplastic features in patients with myelodysplastic syndromes by multicolor flow cytometry
by: O. Yu. Davydova, et al.
Published: (2019-01-01)